MANUEL
MORO SERRANO
Investigador en el periodo 2009-2016
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (3)
2012
-
Five-year antibody persistence and safety following a booster dose of combined haemophilus influenzae type b-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine
Pediatric Infectious Disease Journal, Vol. 31, Núm. 10, pp. 1074-1077
2008
-
Immunogenicity and reactogenicity of a booster dose of a novel combined haemophilus influenzae type b-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age
Pediatric Infectious Disease Journal, Vol. 27, Núm. 7, pp. 579-588
2007
-
Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine coadministered with a diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months
Pediatric Infectious Disease Journal, Vol. 26, Núm. 1, pp. 1-7